You have 0 items in your cart
Price range: £18.95 through £34.95
The PT-141 (Bremelanotide) peptide is a synthetic melanocortin-receptor agonist supplied in freeze-dried (lyophilised) form for laboratory research only. It is not a general-purpose supplement or an approved research-use formulation for self-administration.
Typically supplied as a single peptide compound:
PT-141 (Bremelanotide)
Common research-vial quantities may vary by supplier and formulation.
Lyophilised (freeze-dried) peptide powder
Stored in a sealed laboratory-grade vial
Designed for reconstitution and handling in controlled research environments only
PT-141 is studied in experimental pharmacology, neuroendocrinology, and melanocortin-signalling research, with particular interest in:
Melanocortin receptor activation
Central nervous system signalling pathways
Sexual-behaviour and motivational signalling models
Neuroendocrine regulation
Receptor-mediated behavioural responses
Mechanisms involving melanocortin peptide pathways
PT-141, also known as Bremelanotide, is a synthetic cyclic peptide derived from melanocortin-related compounds.
It acts primarily as an agonist at melanocortin receptors, with activity at MC3R and MC4R among other melanocortin receptor systems.
Research has investigated how activation of these receptors influences central neural signalling and physiological responses, including pathways associated with sexual motivation and behavioural regulation.
Unlike compounds that act primarily through peripheral vascular mechanisms, PT-141 is principally investigated for its effects on melanocortin signalling within the central nervous system.
Researchers commonly use PT-141 to investigate:
Melanocortin receptor pharmacology
MC3R/MC4R signalling pathways
Neuroendocrine signalling mechanisms
Central regulation of sexual behaviour
Motivational and behavioural responses
Receptor activation and downstream signalling
Interactions between melanocortin pathways and other neurological systems
Lyophilised form can provide improved stability compared with an aqueous peptide preparation.
Storage conditions should follow the validated specifications supplied for the particular research material.
After reconstitution, stability may differ substantially depending on concentration, solvent, temperature, container, and handling conditions.
Reconstituted material should therefore be handled according to an appropriate laboratory protocol and should not be assumed to remain stable outside validated conditions.
PT-141 (Bremelanotide) is a pharmacologically active compound and is not a general-purpose laboratory supplement.
Research-grade PT-141 supplied as lyophilised material is not automatically equivalent to a licensed medicinal formulation.
Research material should be used only in appropriately controlled laboratory or preclinical research environments and should not be represented as being suitable for human or veterinary use unless specifically authorised and formulated for that purpose.
The PT-141 (Bremelanotide) peptide is a synthetic melanocortin-receptor agonist supplied in freeze-dried (lyophilised) form for laboratory research only. It is not a general-purpose supplement or an approved research-use formulation for self-administration.
Typically supplied as a single peptide compound:
PT-141 (Bremelanotide)
Common research-vial quantities may vary by supplier and formulation.
Lyophilised (freeze-dried) peptide powder
Stored in a sealed laboratory-grade vial
Designed for reconstitution and handling in controlled research environments only
PT-141 is studied in experimental pharmacology, neuroendocrinology, and melanocortin-signalling research, with particular interest in:
Melanocortin receptor activation
Central nervous system signalling pathways
Sexual-behaviour and motivational signalling models
Neuroendocrine regulation
Receptor-mediated behavioural responses
Mechanisms involving melanocortin peptide pathways
PT-141, also known as Bremelanotide, is a synthetic cyclic peptide derived from melanocortin-related compounds.
It acts primarily as an agonist at melanocortin receptors, with activity at MC3R and MC4R among other melanocortin receptor systems.
Research has investigated how activation of these receptors influences central neural signalling and physiological responses, including pathways associated with sexual motivation and behavioural regulation.
Unlike compounds that act primarily through peripheral vascular mechanisms, PT-141 is principally investigated for its effects on melanocortin signalling within the central nervous system.
Researchers commonly use PT-141 to investigate:
Melanocortin receptor pharmacology
MC3R/MC4R signalling pathways
Neuroendocrine signalling mechanisms
Central regulation of sexual behaviour
Motivational and behavioural responses
Receptor activation and downstream signalling
Interactions between melanocortin pathways and other neurological systems
Lyophilised form can provide improved stability compared with an aqueous peptide preparation.
Storage conditions should follow the validated specifications supplied for the particular research material.
After reconstitution, stability may differ substantially depending on concentration, solvent, temperature, container, and handling conditions.
Reconstituted material should therefore be handled according to an appropriate laboratory protocol and should not be assumed to remain stable outside validated conditions.
PT-141 (Bremelanotide) is a pharmacologically active compound and is not a general-purpose laboratory supplement.
Research-grade PT-141 supplied as lyophilised material is not automatically equivalent to a licensed medicinal formulation.
Research material should be used only in appropriately controlled laboratory or preclinical research environments and should not be represented as being suitable for human or veterinary use unless specifically authorised and formulated for that purpose.
| Quantity | Single, Bundle of 2 |
|---|---|
| Size | Single |
Reviews
There are no reviews yet.